Andrew D Fesnak, MD

faculty photo
Associate Professor of Clinical Pathology and Laboratory Medicine
Attending physician, Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Associate Director, ITMAT Education, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania
Deputy Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania
Director, Hematopoietic Stem Cell Laboratory, Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
3400 Spruce Street
3 Ravdin Building - R3067
Philadelphia, PA 19104
Office: 215-662-3325
Education:
BA (Molecular Biology)
Princeton University, 2005.
MD (Medical Doctorate)
University of Medicine and Dentistry of New Jersey - Robert Wood Johnson School of Medicine, 2011.
MHI (Masters of Health Care Innovation)
University of Pennsylvania, 2019.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Wang K, Tseng CY, Li Z, White C, Wang B, Levine BL, Fesnak AD: A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy. Cytotherapy 25(12): 1370-1379, Dec 2023.

Plesa G, Brennan AL, Levine JR, Hasenmayer D, Buchholz K, Migliaccio T, Holland D, Colligon TA, Mackey S, Dai A, Petrella J, Ngo S, Fesnak A, Davis MM, Siegel D: Multiple Efficiencies Gained by Implementing a Significantly Shorter Manufacturing Schedule for Production of CAR T Cell Products. Cytotherapy. Elsevier, 25(6): S9, May 2023 Notes: 10.1016/S1465-3249(23)00139-1.

Mackey, S. Dai, A. Gong, N. McGettigan, B. Jefferson, P. Petrella, J. Gohil, M. Fesnak, A. Siegel, D. Davis, M. M. Plesa, G.: Developing and Optimizing Multicolor Flow Cytometry Methods for the Manufacturing and Release of 3-Day HuCART Products. Cytotherapy. Elsevier, 25(6): S189-S190, May 2023 Notes: 10.1016/S1465-3249(23)00500-5.

Mack EA, Dougher MC, Ginda A, Cahil CQ, Murter M, Schell K, Tanhehco YC, Bhoj V, Fesnak AD, Siegel DL, Kambayashi T, Aqui N, O'Doherty U: Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis. Blood Online ahead of print 2023.

Fesnak AD, Raval JS: Adverse Events of Cellular and Biotherapies. AABB Technical Manual, 21st edition 2023.

Fesnak AD, Siegel DL: Chimeric antigen receptor T cells and other cellular immunotherapies. Rossi's Principles of Transfusion Medicine, Sixth Edition. Simon TL, Gehrie EA, McCullough J, Roback JD, Snyder EL (eds.). Jul 2022.

Guleria I, de Los Angeles Muñiz M, Wilgo M, Bapat A, Cui W, Hsu YS, Jeyaraman M, Muthu S, Rodriguez F, Fesnak A, Celluzzi C, Sesok-Pizzini D, Reich-Slotky R, Spitzer T.: How do I: Evaluate the safety and legitimacy of unproven cellular therapies? Transfusion 62(3): 518-532, Mar 2022.

Frey NV, Gill S, Hwang WT, Luger SM, Martin ME, McCurdy, SR, Loren AW, Pratz KW, Perl AE, Barber-Rotenberg J, Marshall A, Ruella M, Lacey SF, Fraietta J Fesnak A, O'brien M, Schanne T, Brogdon JL, Engels B, Levine BL, June CH, Porter DL, Hexner EO : CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL. Blood 138(Supplement 1): 469, Dec 2021.

Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, Soto-Calderon H, Grajales L, Starr, J, Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M, Gordon J, Wanicur A, Monroy MA, Mampe F, Lindemuth E, Gouma S, Mullin AM, Barilla H, Pronina A, Irwin L, Thomas R, Eichinger RA, Demuth F, Luning Prak ET, Pascual JL, Short W, Elovitz MA, Baron J, Meyer NJ, Degnan KO, Frank I, Hensley S, Siegel DL, Tebas P: A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest 131(24), Dec 2021.

Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL: Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol 39(27): 3044-3055, Sep 2021.

back to top
Last updated: 01/04/2024
The Trustees of the University of Pennsylvania